STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models

Multiple myeloma (MM) remains an incurable hematological malignancy. Combination regimens of conventional and novel drugs have improved patient’s survival. However, most patients inevitably relapse and become refractory to the current therapeutic armamentarium. We investigated the efficacy of combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozic, Gabriela, Paukov, Lena, Cohen, Ziv, Shapira, Irit, Duek, Adrian, Bejamini, Ohad, Avigdor, Abraham, Nagler, Arnon, Koman, Igor, Leiba, Merav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101139/
https://www.ncbi.nlm.nih.gov/pubmed/30140376
http://dx.doi.org/10.18632/oncotarget.25825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101139/
https://www.ncbi.nlm.nih.gov/pubmed/30140376
http://dx.doi.org/10.18632/oncotarget.25825

Ejemplares similares